论文部分内容阅读
本文探讨了八肽胆囊收缩素CCK-8的抗阿片降压是通过哪种类型的受体完成的,对于非阿片类物质异鹅羔胺的中枢降压效应是否也有对抗作用。结果表明,(1)CCK-8拮抗阿片降压的作用可以被极微量(ng级)的CCK-B受体拮抗剂所阻断,若应用CCK-A拮抗剂则需增加20—40倍剂量才能达到同样效果,说明该效应是CCK-B受体介导的。(2)脊髓蛛网膜下腔内(i.t.)注射异鹅羔胺引起的降压作用既不能被纳洛酮所阻断,也不能被CCK-8所阻断,说明CCK-8对抗阿片肽所引起的降压作用是有一定特异性的,支持了把CCK-8视为一种抗阿片物质的观点。
This article explored the occipital cholecystokinin octapeptide anti-opioid antihypertensive through which type of receptor is completed, the non-opioid islanzine central antihypertensive effect also have antagonistic effect. The results showed that: (1) CCK-8 antagonist opioid hypotensive effect can be blocked by a very small amount (ng level) of CCK-B receptor antagonist, CCK-A antagonists need to increase 20-40 times the dose In order to achieve the same effect, indicating that the effect is CCK-B receptor-mediated. (2) The antihypertensive effect induced by isonazole injection in the spinal subarachnoid (it) can neither be blocked by naloxone nor blocked by CCK-8, indicating that CCK-8 antagonizes opioid peptide The resulting antihypertensive effect is somewhat specific and supports the notion that CCK-8 is considered an anti-opiate.